Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Short Interest Down 6.5% in September

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) saw a significant drop in short interest in September. As of September 30th, there was short interest totalling 5,940,000 shares, a drop of 6.5% from the September 15th total of 6,350,000 shares. Approximately 19.0% of the company’s stock are short sold. Based on an average daily volume of 432,200 shares, the days-to-cover ratio is currently 13.7 days.

Insider Activity

In related news, EVP Shirley R. Kuhlmann sold 19,248 shares of Collegium Pharmaceutical stock in a transaction on Thursday, September 5th. The stock was sold at an average price of $38.30, for a total transaction of $737,198.40. Following the sale, the executive vice president now directly owns 120,161 shares in the company, valued at approximately $4,602,166.30. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In related news, EVP Shirley R. Kuhlmann sold 19,248 shares of Collegium Pharmaceutical stock in a transaction on Thursday, September 5th. The stock was sold at an average price of $38.30, for a total transaction of $737,198.40. Following the sale, the executive vice president now directly owns 120,161 shares in the company, valued at approximately $4,602,166.30. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Thomas B. Smith sold 9,593 shares of Collegium Pharmaceutical stock in a transaction on Friday, September 13th. The stock was sold at an average price of $36.62, for a total value of $351,295.66. Following the sale, the executive vice president now owns 53,816 shares in the company, valued at $1,970,741.92. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 3.98% of the company’s stock.

Hedge Funds Weigh In On Collegium Pharmaceutical

Several hedge funds and other institutional investors have recently added to or reduced their stakes in COLL. ProShare Advisors LLC lifted its stake in shares of Collegium Pharmaceutical by 3.3% in the 1st quarter. ProShare Advisors LLC now owns 8,826 shares of the specialty pharmaceutical company’s stock valued at $343,000 after acquiring an additional 281 shares during the last quarter. Louisiana State Employees Retirement System raised its position in Collegium Pharmaceutical by 1.9% during the 2nd quarter. Louisiana State Employees Retirement System now owns 16,500 shares of the specialty pharmaceutical company’s stock valued at $531,000 after purchasing an additional 300 shares during the last quarter. Texas Permanent School Fund Corp raised its position in Collegium Pharmaceutical by 1.3% during the 1st quarter. Texas Permanent School Fund Corp now owns 28,541 shares of the specialty pharmaceutical company’s stock valued at $1,108,000 after purchasing an additional 369 shares during the last quarter. SummerHaven Investment Management LLC raised its position in Collegium Pharmaceutical by 1.3% during the 2nd quarter. SummerHaven Investment Management LLC now owns 34,773 shares of the specialty pharmaceutical company’s stock valued at $1,120,000 after purchasing an additional 452 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD raised its position in Collegium Pharmaceutical by 1.9% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 29,282 shares of the specialty pharmaceutical company’s stock valued at $1,137,000 after purchasing an additional 535 shares during the last quarter.

Collegium Pharmaceutical Price Performance

Shares of NASDAQ COLL opened at $38.93 on Friday. The stock has a market cap of $1.27 billion, a PE ratio of 16.22 and a beta of 0.94. Collegium Pharmaceutical has a fifty-two week low of $20.95 and a fifty-two week high of $42.29. The company has a debt-to-equity ratio of 1.71, a quick ratio of 1.04 and a current ratio of 1.11. The stock has a fifty day moving average of $37.60 and a 200-day moving average of $35.48.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its quarterly earnings results on Thursday, August 8th. The specialty pharmaceutical company reported $1.62 earnings per share for the quarter, beating the consensus estimate of $1.40 by $0.22. The company had revenue of $145.28 million during the quarter, compared to analysts’ expectations of $143.94 million. Collegium Pharmaceutical had a return on equity of 107.62% and a net margin of 17.32%. The firm’s quarterly revenue was up 7.2% compared to the same quarter last year. During the same period in the previous year, the business earned $1.13 earnings per share. Equities research analysts anticipate that Collegium Pharmaceutical will post 5.79 earnings per share for the current year.

Analysts Set New Price Targets

Several analysts have issued reports on COLL shares. Needham & Company LLC restated a “hold” rating on shares of Collegium Pharmaceutical in a research note on Friday, August 9th. Piper Sandler restated a “neutral” rating and issued a $37.00 target price on shares of Collegium Pharmaceutical in a research note on Friday, October 11th. StockNews.com upgraded Collegium Pharmaceutical from a “buy” rating to a “strong-buy” rating in a research note on Tuesday. Truist Financial boosted their target price on Collegium Pharmaceutical from $40.00 to $42.00 and gave the company a “buy” rating in a research note on Friday, August 9th. Finally, HC Wainwright boosted their target price on Collegium Pharmaceutical from $47.00 to $50.00 and gave the company a “buy” rating in a research note on Thursday, September 5th. Two investment analysts have rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $42.60.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.